Prospective Grant of Exclusive License: Use of Cripto-1 as Claimed in the Licensed Patent Rights, for the Development of a FDA Approved Diagnostic Kit for Human Cancers, 30022 [E7-10352]
Download as PDF
<![CDATA[
sroberts on PROD1PC70 with NOTICES
30022
Federal Register / Vol. 72, No. 103 / Wednesday, May 30, 2007 / Notices
Health, 6701 Rockledge Drive, Room 4206,
MSC 7812, Bethesda, MD 20892, 301–435–
1223, haydenb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Parasites.
Date: June 27, 2007.
Time: 1:30 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Marian Wachtel, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3208,
MSC 7858, Bethesda, MD 20892, 301–435–
1148, wachtelm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Complex
Human Genetics.
Date: June 28–29, 2007.
Time: 9 a.m. to 11:59 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Camilla E. Day, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5148,
MSC 7890, Bethesda, MD 20892, (301) 435–
1037, dayc@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; ZRG1
BDCN–F (12) Visual System Small Business.
Date: June 29, 2007.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Biao Tian, PhD, Scientific
Review Administrator, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 3166, MSC 7848,
Bethesda, MD 20892, 301–402–4411,
tianbi@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Insulin
Action.
Date: June 29, 2007.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Krish Krishnan, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6164,
MSC 7892, Bethesda, MD 20892, (301) 435–
1041, krishnak@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
VerDate Aug<31>2005
19:13 May 29, 2007
Jkt 211001
Dated: May 22, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–2670 Filed 5–29–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of Cripto-1 as Claimed in
the Licensed Patent Rights, for the
Development of a FDA Approved
Diagnostic Kit for Human Cancers
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent No. 7,078,176;
European Patent No. 1370869 and PCT
Application No. PCT/US02/02225 and
foreign equivalents thereof entitled
‘‘Detection and quantification of Cripto1’’ (E–290–2000/0), to Biosite, Inc,
which is located in San Diego,
California. The patent rights in these
inventions have been assigned to the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of the Licensed Patent Rights, for the
development of a FDA approved
diagnostic kit for human cancers.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before July
30, 2007 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Michelle A. Booden,
Ph.D., Technology Licensing Specialist,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 451–
7337; Facsimile: (301) 402–0220; E-mail:
boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: Cripto-1
(CR1) is a member of the epidermal
growth factor (EGF)-related families of
peptides and is involved in the
development and progression of various
human carcinomas. In particular, CR1
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
overexpression has been detected in 50–
90% of carcinomas of the colon,
pancreas, stomach, gallbladder, breast,
lung, endometrium and cervix. Current
methodologies of cancer detection, e.g.
immunohistochemistry, can be time
consuming, inconvenient and
oftentimes, inaccurate, and therefore, a
need exists for more efficient, reliable
and less time consuming methods of
detection. The invention relates to such
a method of detection. The inventors
disclose methods for the detection and
quantification of CR1 in human milk,
using an ELISA-based protocol. This test
could also be used to more effectively
detect and perhaps stage cancers.
Additionally, should particular tumor
cells, e.g. breast tumor cells, express a
sufficiently high level of CR1, it may be
possible to use the assay to detect and
measure CR1 in human serum and/or
plasma.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: May 22, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–10352 Filed 5–29–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of Anti-HIV
Therapeutics, Anti-HIV Topical
Microbicides, and Anti-Breast Cancer
Therapeutics
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
E:\FR\FM\30MYN1.SGM
30MYN1
]]>Agencies
[Federal Register Volume 72, Number 103 (Wednesday, May 30, 2007)]
[Notices]
[Page 30022]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-10352]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Cripto-1 as
Claimed in the Licensed Patent Rights, for the Development of a FDA
Approved Diagnostic Kit for Human Cancers
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department
of Health and Human Services, is contemplating the grant of an
exclusive patent license to practice the inventions embodied in U.S.
Patent No. 7,078,176; European Patent No. 1370869 and PCT Application
No. PCT/US02/02225 and foreign equivalents thereof entitled ``Detection
and quantification of Cripto-1'' (E-290-2000/0), to Biosite, Inc, which
is located in San Diego, California. The patent rights in these
inventions have been assigned to the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of the Licensed Patent
Rights, for the development of a FDA approved diagnostic kit for human
cancers.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before July
30, 2007 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Michelle A. Booden, Ph.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; E-
mail: boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: Cripto-1 (CR1) is a member of the epidermal
growth factor (EGF)-related families of peptides and is involved in the
development and progression of various human carcinomas. In particular,
CR1 overexpression has been detected in 50-90% of carcinomas of the
colon, pancreas, stomach, gallbladder, breast, lung, endometrium and
cervix. Current methodologies of cancer detection, e.g.
immunohistochemistry, can be time consuming, inconvenient and
oftentimes, inaccurate, and therefore, a need exists for more
efficient, reliable and less time consuming methods of detection. The
invention relates to such a method of detection. The inventors disclose
methods for the detection and quantification of CR1 in human milk,
using an ELISA-based protocol. This test could also be used to more
effectively detect and perhaps stage cancers. Additionally, should
particular tumor cells, e.g. breast tumor cells, express a sufficiently
high level of CR1, it may be possible to use the assay to detect and
measure CR1 in human serum and/or plasma.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, the NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 22, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-10352 Filed 5-29-07; 8:45 am]
BILLING CODE 4140-01-P
